Lapatinib for Advanced or Metastatic Breast Cancer
- 1 April 2012
- journal article
- review article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 17 (4), 536-542
- https://doi.org/10.1634/theoncologist.2011-0461
Abstract
Lapatinib is a potent reversible and selective inhibitor of the tyrosine kinase domains of epidermal growth factor receptor and human epidermal growth factor receptor (HER)-2 that exerts its action by competitive binding to the intracellular ATP-binding site of the receptor. It is registered for the treatment of advanced or metastatic HER-2+ breast cancer in combination with capecitabine and for hormone receptor–positive breast cancer in combination with an aromatase inhibitor. Lapatinib administered orally once daily is moderately to well tolerated, with rash and gastrointestinal adverse events as the main toxicities. In studies on the efficacy of lapatinib, direct comparisons between lapatinib and trastuzumab are lacking. Results of ongoing randomized phase III studies with lapatinib or trastuzumab in combination with taxanes as first-line agents for metastatic breast cancer as well as in the neoadjuvant and adjuvant settings are awaited.Keywords
This publication has 30 references indexed in Scilit:
- Lapatinib Plus Capecitabine in Women with HER-2–Positive Advanced Breast Cancer: Final Survival Analysis of a Phase III Randomized TrialThe Oncologist, 2010
- Mechanism-Based Inactivation of Cytochrome P450 3A4 by LapatinibMolecular Pharmacology, 2010
- An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancerAnnals of Oncology, 2010
- Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast CancerJournal of Clinical Oncology, 2009
- A Phase I and Pharmacokinetic Study of Oral Lapatinib Administered Once or Twice Daily in Patients with Solid MalignanciesClinical Cancer Research, 2009
- Effects of ketoconazole and carbamazepine on lapatinib pharmacokinetics in healthy subjectsBritish Journal of Clinical Pharmacology, 2009
- Effects of Food on the Relative Bioavailability of Lapatinib in Cancer PatientsJournal of Clinical Oncology, 2009
- Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast CancerJournal of Clinical Oncology, 2008
- A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analysesBreast Cancer Research and Treatment, 2008
- A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecanAnnals of Oncology, 2007